Evidence map›Paper›PMID 39166271›Full record

ArticleAnnals of medicine2024

Real-world status, efficacy and prognosis analysis of first-line treatment for unresectable hepatocellular carcinoma in patients treated at multiple centres.

Jing Liu, Qianyu Du, Yu Shao, Han Xu, Xiuli Liu, Wenting Zhang, Mingxi Wang, Zhengguang Zhou, Qingsheng Kan, Yan Yang

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jing LiuDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.ORCID 0000-0002-5118-9259
Qianyu DuDepartment of Oncology, Suzhou Hospital Affiliated to Anhui Medical University, Suzhou, China.
Yu ShaoNational Drug Clinical Trial Centre, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Han XuDepartment of Medical Oncology, The Third People's Hospital of Bengbu, Bengbu, China.
Xiuli LiuDepartment of Oncology, The Fifth People's Hospital of Fuyang, Fuyang, China.
Wenting ZhangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Mingxi WangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Zhengguang ZhouDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Qingsheng KanDepartment of Oncology, Suzhou Hospital Affiliated to Anhui Medical University, Suzhou, China.
Yan YangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.ORCID 0000-0003-0887-2770

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo present the real-world status and explore the predictors of the efficacy and prognosis of first-line treatment for unresectable hepatocellular carcinoma (uHCC).

methodsReal-world data of uHCC patients who underwent first-line treatment at 4 hospitals in Northern Anhui, China, from July 2019 to December 2022 were retrospectively collected. The clinicopathological features, haematological indicators, including superoxide dismutase (SOD) and vascular endothelial growth factor-A (VEGF-A), efficacy and safety data were analysed.

resultsA total of 153 patients were enrolled and most of them treated with targeted therapy combined with immunotherapy (TI). Compared to patients treated with TI, patients who were administrated with TI plus locoregional therapy (TIL) showed longer median progression-free survival (mPFS) and median overall survival (mOS) times (both

conclusionsTI was the most commonly first-line systemic therapy for uHCC patients, with better efficacy and outcomes when combined with locoregional therapy in a certain population. Baseline serum SOD and VEGF-A were found to be potential predictive biomarkers for decision-making, treatment response, and outcome in patients with uHCC in the primary care setting.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsVascular Endothelial Growth Factor AAdultAgedChinaFemaleHumansImmunotherapyMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesSuperoxide DismutaseTreatment OutcomeSuperoxide DismutaseVascular Endothelial Growth Factor AVEGFA protein, humanefficacyHepatocellular carcinomaimmunotherapylocoregional therapyprognosissuperoxide dismutasetargeted therapyvascular endothelial growth factor A

Identifiers

PMID39166271
PMCPMC11340225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.